Comparative effectiveness of H7N9 vaccines in healthy individuals

References

• Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368:1888–1897. doi:10.1056/NEJMoa1304459.
   PubMed Web of Science ®Google Scholar
• W.H.O. Situation updates - Avian influenza. http://www.who.int/influenza/human_animal_interface/avian_influenza/archive/en/.
   Google Scholar
• Liu D, Shi W, Shi Y, Wang D, Xiao H, Li W, Bi Y, Wu Y, Li X, Yan J, et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet. 2013;381:1926–1932. doi:10.1016/S0140-6736(13)60938-1.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J, Yao H, Wo J, Fang Q, Cui D, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet. 2013;381:1916–1925. doi:10.1016/S0140-6736(13)60903-4.
   PubMed Web of Science ®Google Scholar
• Srinivasan K, Raman R, Jayaraman A, Viswanathan K, Sasisekharan R. 2013. Quantitative description of glycan-receptor binding of influenza A virus H7 hemagglutinin. PLoS One. 8:e49597. doi:10.1371/journal.pone.0049597.
   PubMed Web of Science ®Google Scholar
• Yang H, Chen LM, Carney PJ, Donis RO, Stevens J. 2010. Structures of receptor complexes of a North American H7N2 influenza hemagglutinin with a loop deletion in the receptor binding site. PLoS Pathog. 6:e1001081. doi:10.1371/journal.ppat.1000975.
   PubMed Web of Science ®Google Scholar
• Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada S, Uchida Y, Neumann G, Saito T, Kawaoka Y, Tashiro M. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China. Eurosurveillance. 18;2013:20453.
   Web of Science ®Google Scholar
• Matsuoka Y, Swayne DE, Thomas C, Rameix-Welti MA, Naffakh N, Warnes C, Altholtz M, Donis R, Subbarao K. 2009. Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice. J Virol. 83:4704–4708. doi:10.1128/JVI.01987-08.
   PubMed Web of Science ®Google Scholar
• Gabriel G, Dauber B, Wolff T, Planz O, Klenk HD, Stech J. 2005. The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. Proc Natl Acad Sci USA. 102:18590–18595. doi:10.1073/pnas.0507415102.
   PubMed Web of Science ®Google Scholar
• Hudjetz B, Gabriel G. 2012. Human-like PB2 627K influenza virus polymerase activity is regulated by importin-α1 and -α7. PLoS Pathog. 8:e1002488. doi:10.1371/journal.ppat.1002488.
   PubMed Web of Science ®Google Scholar
• Li Z, Chen H, Jiao P, Deng G, Tian G, Li Y, Hoffmann E, Webster RG, Matsuoka Y, Yu K. 2005. Molecular basis of replication of duck H5N1 influenza viruses in a mammalian mouse model. J Virol. 79:12058–12064. doi:10.1128/JVI.79.18.12058-12064.2005.
   PubMed Web of Science ®Google Scholar
• Lai KY, Ng GWY, Wong KF, Hung IFN, Hong JKF, Cheng FF, Chan JKC. 2013. Human H7N9 avian influenza virus infection: a review and pandemic risk assessment. Emerg Microbes Infect. 2:e48. doi:10.1038/emi.2013.48.
   PubMedGoogle Scholar
• Kang HM, Park HY, Lee KJ, Choi JG, Lee EK, Song BM, Lee HS, Lee YJ. 2014. Characterization of H7 influenza A virus in wild and domestic birds in Korea. PLoS One. 9:e91887. doi:10.1371/journal.pone.0091887.
   PubMed Web of Science ®Google Scholar
• Yu L, Wang Z, Chen Y, Ding W, Jia H, Chan JFW, To KKW, Chen H, Yang Y, Liang W, et al. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A(H7N9) virus. Clin Infect Dis. 2013;57:1449–1457. doi:10.1093/cid/cit541.
   PubMed Web of Science ®Google Scholar
• Catherine JL, Kanta S. 2006. Vaccines for pandemic influenza. Emerg Infect Dis. 12:66–72. doi:10.3201/eid1201.051147.
   PubMed Web of Science ®Google Scholar
• Lars RH, Abdullah SM, Rebecca C. 2009. Pandemic influenza vaccines - The challenges. Viruses. 1:1089–1109. doi:10.3390/v1031089.
   PubMed Web of Science ®Google Scholar
• Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M, Vogel FR, Barclay W, et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine. 2009;27:1889–1897. doi:10.1016/j.vaccine.2009.01.116.
   PubMed Web of Science ®Google Scholar
• Couch RB, Patel SM, Wade-Bowers CL, Niño D. 2012. A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One. 7:e49704. doi:10.1371/journal.pone.0049704.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 17;1996:1–12.
   PubMedGoogle Scholar
• Sobhanie M, Matsuoka Y, Jegaskanda S, Fitzgerald T, Mallory R, Chen Z, Luke C, Treanor J, Subbarao K. 2016. Evaluation of the safety and immunogenicity of a candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9). J Infect Dis. 213:922–929. doi:10.1093/infdis/jiv526.
   PubMed Web of Science ®Google Scholar
• Fries LF, Smith GE, Glenn GM. 2013. A Recombinant Viruslike Particle Influenza A (H7N9) vaccine. N Engl J Med. 369:2564–2566. doi:10.1056/NEJMc1313186.
   PubMed Web of Science ®Google Scholar
• Bart SA, Hohenboken M, Cioppa GD, Narasimhan V, Dormitzer PR, Kanesa-Thasan N. 2014. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med. 6:234ra55. doi:10.1126/scitranslmed.3008761.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, Dickey M, Stapleton JT, Edupuganti S, Spearman P, et al. Serological responses to an avian influenza AH7N9 vaccine mixed at the point-of-use with MF59 adjuvant a randomized clinical trial. JAMA. 2014;312:1409–1419. doi:10.1001/jama.2014.12854.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech CB, et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: A randomized clinical trial. JAMA. 2015;314:237–246. doi:10.1001/jama.2015.7916.
   PubMed Web of Science ®Google Scholar
• Madan A, Segall N, Ferguson M, Frenette L, Kroll R, Friel D, Soni J, Li P, Innis BL, Schuind A. 2016. Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults. J Infect Dis. 214:1717–1727. doi:10.1093/infdis/jiw414.
   PubMed Web of Science ®Google Scholar
• Wu UI, Hsieh SM, Lee WS, Wang NC, Kung HC, Ou TY, Chen FL, Lin TY, Chen YC, Chang SC. 2017. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults A phase I/II,prospective, randomized, open-label trial. Vaccine. 35:4099–4104. doi:10.1016/j.vaccine.2017.06.044.
   PubMed Web of Science ®Google Scholar
• Rudenko L, Isakova-Sivak I, Naykhin A, Kiseleva I, Stukova M, Erofeeva M, Korenkov D, Matyushenko V, Sparrow E, Kieny MP. 2016. H7N9 live attenuated influenza vaccine in healthy adults a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 16:303–310. doi:10.1016/S1473-3099(15)00378-3.
   PubMed Web of Science ®Google Scholar
• DeZure AD, Coates EE, Hu Z, Yamshchikov GV, Zephir KL, Enama ME, Plummer SH, Gordon IJ, Kaltovich F, Andrews S, et al. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. NPJ Vaccines. 2017;2:15. doi:10.1038/s41541-017-0016-6.
   PubMed Web of Science ®Google Scholar
• Wise J. 2018. WHO is “cautiously optimistic” about Ebola ring vaccination programme in DRC. BMJ. 361:k2388. doi:10.1136/bmj.k2388.
   PubMedGoogle Scholar
• WHO planning for ‘worst case scenario’ over DRC Ebola outbreak. www.aljazeera.com.
   Google Scholar
• Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC. 2001. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet. 357:1937–1943. doi:10.1016/S0140-6736(00)05066-2.
   PubMed Web of Science ®Google Scholar
• Atmar RL, Keitel WA, Patel SM, Katz JM, She D, Sahly HE, Pompey J, Cate TR, Couch RB. 2006. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 43:1135–1142. doi:10.1086/508174.
   PubMed Web of Science ®Google Scholar
• Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM. 2005. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis. 191:1210–1215. doi:10.1086/428948.
   PubMed Web of Science ®Google Scholar
• De GE, Tritto E, Rappuoli R. 2008. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol. 38:2068–2071. doi:10.1002/eji.200838648.
   PubMed Web of Science ®Google Scholar
• Teena M, Priyanka V, Nageswara R. Novel adjuvants & delivery vehicles for vaccines development: A road ahead. Indian J Med Res. 138;2013:779–795.
   PubMed Web of Science ®Google Scholar
• Nikolai P. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine. 24;2006:S2-26-9.
   Web of Science ®Google Scholar
• Atmar RL, Keitel WA. 2009. Adjuvants for pandemic influenza vaccines. Curr Top Microbiol Immunol. 333:323–344. doi:10.1007/978-3-540-92165-3_16.
   PubMedGoogle Scholar
• O’Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. 2013. The history of MF59® adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines. 12:13–30. doi:10.1586/erv.12.140.
   PubMed Web of Science ®Google Scholar
• Podda A, Giudice GD. 2003. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines. 2:197–203. doi:10.1586/14760584.2.2.197.
   PubMedGoogle Scholar
• Black S, Cioppa GD, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A. 2010. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine. 28:7331–7336. doi:10.1016/j.vaccine.2010.08.075.
   PubMed Web of Science ®Google Scholar
• Tsai TF, Crucitti A, Nacci P, Nicolay U, Cioppa GD, Ferguson J, Clemens R. 2011. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis. 43:702–706. doi:10.3109/00365548.2011.580777.
   PubMed Web of Science ®Google Scholar
• Madan A, Collins H, Sheldon E, Frenette L, Chu L, Friel D, Drame M, Vaughn DW, Innis BL, Schuind A. 2017. Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial. Vaccine. 35:4621–4628. doi:10.1016/j.vaccine.2017.07.013.
   PubMed Web of Science ®Google Scholar
• Most R, Clément F, Willekens J, Dewé W, Walravens K, Vaughn DW, Leroux-Roels G. 2017. Long-term persistence of cell-mediated and humoral responses to A(H1N1)pdm09 influenza virus vaccines and the role of the AS03 adjuvant system in adults during two randomized controlled trials. Clin Vaccine Immunol. 24:e00553–00516. doi:10.1128/CVI.00553-16.
   PubMed Web of Science ®Google Scholar
• Chung KY, Coyle EM, Jani D, King LR, Bhardwaj R, Fries L, Smith G, Glenn G, Golding H, Khurana S. 2015. ISCOMATRIXTM adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine. Vaccine. 33:3953–3962. doi:10.1016/j.vaccine.2015.06.047.
   PubMed Web of Science ®Google Scholar
• Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E. 2012. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. J Med Microbiol. 61:935–943. doi:10.1099/jmm.0.040857-0.
   PubMed Web of Science ®Google Scholar
• Marina U, Andrej T, Mirjana H, Lars H. 2001. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun. 69:1151–1159. doi:10.1128/IAI.69.2.1151-1159.2001.
   PubMed Web of Science ®Google Scholar
• Norimatsu M, Ogikubo Y, Aoki A, Takahashi T, Watanabe G, Taya K, Sasamoto S, Tsuchiya M, Tamura Y. Effects of aluminum adjuvant on systemic reactions of lipopolysaccharides in swine. Vaccine. 13;1995:1325–1329.
   PubMed Web of Science ®Google Scholar
• Shi Y, HogenEsch H, Regnier FE, Hem SL. Detoxification of endotoxin by aluminum hydroxide adjuvant. Vaccine. 19;2001:1747–1752.
   PubMed Web of Science ®Google Scholar
• Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O’Hagan DT, Gregorio ED, Seubert A, Wack A. 2011. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine. 29:1812–1823. doi:10.1016/j.vaccine.2010.12.090.
   PubMed Web of Science ®Google Scholar
• Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O’Hagan D, Rappuoli R, Gregorio ED. 2008. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA. 105:10501–10506. doi:10.1073/pnas.0804699105.
   PubMed Web of Science ®Google Scholar
• Tetsutani K, Ishii KJ. 2012. Adjuvants in influenza vaccines. Vaccine. 30:7658–7661. doi:10.1016/j.vaccine.2012.10.007.
   PubMed Web of Science ®Google Scholar
• Geeraedts F, Goutagny N, Hornung V, Severa M, Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A. 2008. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signaling. PLoS Pathog. 4:e1000138. doi:10.1371/journal.ppat.1000138.
   PubMed Web of Science ®Google Scholar
• Cheng VCC, To KKW, Tse H, Hung IFN, Yuen KY. 2012. Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev. 25:223–263. doi:10.1128/CMR.05012-11.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhu WF, Li XY, Chen MM, Wu J, Yu PB, Qi SX, Huang YW, Shi WX, Dong J, et al. Genesis and spread of newly emerged highly pathogenic H7N9 avian viruses in Mainland China. J Virol. 2017;91:e01277–17. doi:10.1128/JVI.01277-17.
   PubMed Web of Science ®Google Scholar
• Qi X, An X, Jiao Y, Yu H, Xu K, Cui L, Wang S, Deng F, Huo X, Huang H, et al. Co-circulation of multiple genotypes of influenza A (H7N9) viruses in eastern China, 2016-2017. Arch Virol. 2018;163:1779–1793. doi:10.1007/s00705-018-3800-3.
   PubMed Web of Science ®Google Scholar
• W.H.O. Surveillance and monitoring. http://www.who.int/influenza/surveillance_monitoring/en/.
   Google Scholar
• Naruse T, Fukuda T, Tanabe T, Ichikawa M, Oda Y, Tochihara S, Kimachi K, Kino Y, Ueda K. 2015. A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03. Vaccine. 33:6078–6084. doi:10.1016/j.vaccine.2015.09.022.
   PubMed Web of Science ®Google Scholar